141 related articles for article (PubMed ID: 25411805)
1. Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center.
Kavecansky J; Wei L; Caronia L; Ramirez MT; Bloomston M; Shah MH
Pancreas; 2015 Mar; 44(2):198-203. PubMed ID: 25411805
[TBL] [Abstract][Full Text] [Related]
2. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
3. Bone metastases in neuroendocrine tumors.
Zamborsky R; Svec A; Kokavec M; Galbavy S
Bratisl Lek Listy; 2017; 118(9):529-534. PubMed ID: 29061059
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.
Strosberg D; Schneider EB; Onesti J; Saunders N; Konda B; Shah M; Dillhoff M; Schmidt CR; Shirley LA
Ann Surg Oncol; 2018 Nov; 25(12):3613-3620. PubMed ID: 30182331
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
6. Surgery for metastatic neuroendocrine tumors with occult primaries.
Bartlett EK; Roses RE; Gupta M; Shah PK; Shah KK; Zaheer S; Wachtel H; Kelz RR; Karakousis GC; Fraker DL
J Surg Res; 2013 Sep; 184(1):221-7. PubMed ID: 23643298
[TBL] [Abstract][Full Text] [Related]
7. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
8. A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.
Boudreaux JP; Wang YZ; Diebold AE; Frey DJ; Anthony L; Uhlhorn AP; Ryan P; Woltering EA
J Am Coll Surg; 2014 Apr; 218(4):837-44. PubMed ID: 24655881
[TBL] [Abstract][Full Text] [Related]
9. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
10. Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum.
Woltering EA; Beyer DT; Thiagarajan R; Ramirez RA; Wang YZ; Ricks MJ; Boudreaux JP
J Am Coll Surg; 2016 Apr; 222(4):534-42. PubMed ID: 26827125
[TBL] [Abstract][Full Text] [Related]
11. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
[TBL] [Abstract][Full Text] [Related]
12. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
13. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
14. Skeletal-related events due to bone metastases from differentiated thyroid cancer.
Farooki A; Leung V; Tala H; Tuttle RM
J Clin Endocrinol Metab; 2012 Jul; 97(7):2433-9. PubMed ID: 22564664
[TBL] [Abstract][Full Text] [Related]
15. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.
Strosberg J; Gardner N; Kvols L
Neuroendocrinology; 2009; 89(4):471-6. PubMed ID: 19174605
[TBL] [Abstract][Full Text] [Related]
16. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).
Yong M; Jensen AÖ; Jacobsen JB; Nørgaard M; Fryzek JP; Sørensen HT
Breast Cancer Res Treat; 2011 Sep; 129(2):495-503. PubMed ID: 21461730
[TBL] [Abstract][Full Text] [Related]
17. Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance.
Scharf M; Petry V; Daniel H; Rinke A; Gress TM
Neuroendocrinology; 2018; 106(1):30-37. PubMed ID: 28152537
[TBL] [Abstract][Full Text] [Related]
18. Small intestinal neuroendocrine tumors: prognostic factors and survival.
Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Metastases in Rectal Neuroendocrine Tumors: Results of a National Cohort Study.
Concors SJ; Sinnamon AJ; Folkert IW; Mahmoud NN; Fraker DL; Paulson EC; Roses RE
Dis Colon Rectum; 2018 Dec; 61(12):1372-1379. PubMed ID: 30312223
[TBL] [Abstract][Full Text] [Related]
20. Massive endoprosthetic replacement for bone metastases resulting from renal cell carcinoma: factors influencing patient survival.
Hwang N; Nandra R; Grimer RJ; Carter SR; Tillman RM; Abudu A; Jeys LM
Eur J Surg Oncol; 2014 Apr; 40(4):429-34. PubMed ID: 24063967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]